Table 1

Surgical and pathological data comparing patients with metastatic and non-metastatic lymph nodes present in anterior prostatic fat

Patients with metastatic APF lymph nodes (n=4)Patients with non-metastatic APF lymph nodes (n=45)Patients without APF lymph nodes (n=233)
Mean age at surgery (range)63.8 (62–65)63 (44–73)64 (43–76)
Preop PSA, ng/mL (%)
 0–3.91 (25.0)2 (4.4)9 (3.9)
 4–101 (25.0)21 (46.7)134 (57.5)
 >102 (50.0)22 (48.9)90 (38.6)
Preop histology (%)
 3+3=61 (25.0)11 (24.4)89 (38.2)
 3+4=71 (25.0)24 (53.3)111 (47.6)
 4+3=71 (25.0)8 (17.8)30 (12.9)
 ≥81 (25.0)2 (4.4)3 (1.3)
Pathological T stage (%)
 pT21 (25.0)27 (60.0)145 (62.2)
 pT33 (75.0)18 (40.0)88 (37.8)
 Mean total tumour volume, mL (range)8.68 (2.1–12.3)3.7 (0.1–15)3.85 (0.01–38)
 Anterior primary tumour (%)4 (100)8 (17.7)54 (23.2)
 Vascular invasion (%)1 (25.0)4 (8.9)14 (6.0)
 Seminal vesicle invasion, n (%)1 (25.0)5 (11.1)16 (6.9)
Pathological Gleason score (%)
 No tumour1 (0.4)
 3+3=611 (24.4)51 (21.9)
 3+4=720 (44.4)128 (54.9)
 4+3=71 (25.0)13 (28.9)40 (17.2)
 >83 (75.0)1 (2.2)13 (5.6)
  • APF, anterior prostatic fat; PSA, prostrate specific antigen.